Insider Selling: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) SVP Sells 5,360 Shares of Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) SVP Andrew Davis sold 5,360 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $21,868.80. Following the completion of the transaction, the senior vice president now directly owns 284,685 shares of the company’s stock, valued at approximately $1,161,514.80. This trade represents a 1.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock traded down $0.29 during mid-day trading on Wednesday, hitting $3.52. 1,613,600 shares of the company were exchanged, compared to its average volume of 2,895,659. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.51 and a 12-month high of $15.70. The company has a market capitalization of $563.31 million, a P/E ratio of -127.00 and a beta of 0.47. The business’s 50 day simple moving average is $4.27 and its two-hundred day simple moving average is $5.39.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million during the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company’s revenue was down 19.4% compared to the same quarter last year. During the same period last year, the company posted $0.12 earnings per share. Equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Craig Hallum lowered their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Wells Fargo & Company dropped their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Finally, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $10.40.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. CWM LLC boosted its position in Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 2,345 shares during the period. KBC Group NV grew its holdings in shares of Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,198 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $91,000. GAMMA Investing LLC boosted its position in Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares during the period. Finally, EntryPoint Capital LLC raised its stake in Ironwood Pharmaceuticals by 517.4% during the first quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 8,874 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.